Table of Contents Author Guidelines Submit a Manuscript
Journal of Pregnancy
Volume 2011 (2011), Article ID 176973, 6 pages
http://dx.doi.org/10.1155/2011/176973
Review Article

Renal Involvement in Preeclampsia: Similarities to VEGF Ablation Therapy

Division of Nephrology and Hypertension, Department of Medicine, IFB-TX Hannover, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany

Received 11 September 2010; Accepted 1 November 2010

Academic Editor: David F. Lewis

Copyright © 2011 Janina Müller-Deile and Mario Schiffer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. J. Walker, “Pre-eclampsia,” Lancet, vol. 356, no. 9237, pp. 1260–1265, 2000. View at Google Scholar · View at Scopus
  2. H. He, V. J. Venema, X. Gu, R. C. Venema, M. B. Marrero, and R. B. Caldwell, “Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/KDR activation of c-Src,” Journal of Biological Chemistry, vol. 274, no. 35, pp. 25130–25135, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Simon, H. J. Grone, O. Johren et al., “Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney,” American Journal of Physiology—Renal Fluid and Electrolyte Physiology, vol. 268, no. 2, pp. F240–F250, 1995. View at Google Scholar · View at Scopus
  4. S. E. Maynard, J. Y. Min, J. Merchan et al., “Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction hypertension, and proteinuria in preeclampsia,” Journal of Clinical Investigation, vol. 111, no. 5, pp. 649–658, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. A. de Vivo, G. Baviera, D. Giordano, G. Todarello, F. Corrado, and R. D'Anna, “Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia,” Acta Obstetricia et Gynecologica Scandinavica, vol. 87, no. 8, pp. 837–842, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. J. C. Yang, L. Haworth, R. M. Sherry et al., “A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer,” New England Journal of Medicine, vol. 349, no. 5, pp. 427–434, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. B. C. Kuenen, M. Levi, J. C. M. Meijers et al., “Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 9, pp. 1500–1505, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. T. V. Patel, J. A. Morgan, G. D. Demetri et al., “A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib,” Journal of the National Cancer Institute, vol. 100, no. 4, pp. 282–284, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. R. R. Foster, R. Hole, K. Anderson et al., “Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes,” American Journal of Physiology—Renal Physiology, vol. 284, no. 6, pp. F1263–F1273, 2003. View at Google Scholar · View at Scopus
  10. J. Müller-Deile, K. Worthmann, M. Saleem, I. Tossidou, H. Haller, and M. Schiffer, “The balance of autocrine VEGF-A and VEGF-C determines podocyte survival,” American Journal of Physiology—Renal Physiology, vol. 297, no. 6, pp. F1656–F1667, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. V. Eremina, H. J. Baelde, and S. E. Quaggin, “Role of the VEGF-A signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier,” Nephron Physiology, vol. 106, no. 2, pp. p32–p37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Sison, V. Eremina, H. Baelde et al., “Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling,” Journal of the American Society of Nephrology, vol. 21, no. 10, pp. 1691–1701, 2010. View at Publisher · View at Google Scholar
  13. V. D. Garovic, S. J. Wagner, S. T. Turner et al., “Urinary podocyte excretion as a marker for preeclampsia,” American Journal of Obstetrics and Gynecology, vol. 196, no. 4, pp. 320.e1–320.e7, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Hertig, N. Berkane, G. Lefevre et al., “Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia,” Clinical Chemistry, vol. 50, no. 9, pp. 1702–1703, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. V. D. Garovic, S. J. Wagner, L. M. Petrovic et al., “Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia,” Nephrology Dialysis Transplantation, vol. 22, no. 4, pp. 1136–1143, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Sugimoto, Y. Hamanog, D. Charytan et al., “Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria,” Journal of Biological Chemistry, vol. 278, no. 15, pp. 12605–12608, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. M. S. Gordon and D. Cunningham, “Managing patients treated with bevacizumab combination therapy,” Oncology, vol. 69, no. 3, pp. 25–33, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. B. A. George, X. J. Zhou, and R. Toto, “Nephrotic syndrome after bevacizumab: case report and literature review,” American Journal of Kidney Diseases, vol. 49, no. 2, pp. e23–e29, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Ostendorf, U. Kunter, F. Eitner et al., “VEGf mediates glomerular endothelial repair,” Journal of Clinical Investigation, vol. 104, no. 7, pp. 913–923, 1999. View at Google Scholar · View at Scopus
  20. S. A. Karumanchi, S. E. Maynard, I. E. Stillman, F. H. Epstein, and V. P. Sukhatme, “Preeclampsia: a renal perspective,” Kidney International, vol. 67, no. 6, pp. 2101–2113, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Aita, M. Etoh, H. Hamada et al., “Acute and transient podocyte loss and proteinuria in preeclampsia,” Nephron Clinical Practice, vol. 112, no. 2, pp. c65–c70, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Yu, A. Petermann, U. Kunter, S. Rong, S. J. Shankland, and J. Floege, “Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria,” Journal of the American Society of Nephrology, vol. 16, no. 6, pp. 1733–1741, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Achenbach, M. Mengel, I. Tossidou et al., “Parietal epithelia cells in the urine as a marker of disease activity in glomerular diseases,” Nephrology Dialysis Transplantation, vol. 23, no. 10, pp. 3138–3145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Müller-Deile, V. Bröcker, V. Grünwald et al., “Renal side effects of VEGF-blocking therapy,” NDT Plus, vol. 3, no. 2, pp. 172–175, 2010. View at Publisher · View at Google Scholar
  25. E. S. Robinson, U. A. Matulonis, P. Ivy et al., “Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 3, pp. 477–483, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Hertig, “Anti-vascular endothelial growth factor (VEGF) therapy: a new cause of hypertension,” Revue du Praticien, vol. 60, no. 5, pp. 644–648, 2010. View at Google Scholar · View at Scopus
  27. B. Li, A. K. Ogasawara, R. Yang et al., “KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF,” Hypertension, vol. 39, no. 6, pp. 1095–1100, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. R. S. Scotland, M. Madhani, S. Chauhan et al., “Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo,” Circulation, vol. 111, no. 6, pp. 796–803, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Yang, A. K. Ogasawara, T. F. Zioncheck et al., “Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats,” Hypertension, vol. 39, no. 3, pp. 815–820, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Okuda, K. Tsurumaru, S. Suzuki et al., “Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells,” Life Sciences, vol. 63, no. 6, pp. 477–484, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. J. S. Gilbert, J. Verzwyvelt, D. Colson, M. Arany, S. A. Karumanchi, and J. P. Granger, “Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placental ischemia-induced hypertension,” Hypertension, vol. 55, no. 2, pp. 380–385, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. Z. Li, Y. Zhang, J. Y. Ma et al., “Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia,” Hypertension, vol. 50, no. 4, pp. 686–692, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. H. M. W. Verheul and H. M. Pinedo, “Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition,” Nature Reviews Cancer, vol. 7, no. 6, pp. 475–485, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. S. E. Quaggin and T. M. Coffman, “Toward a mouse model of diabetic nephropathy: is endothelial nitric oxide synthase the missing link?” Journal of the American Society of Nephrology, vol. 18, no. 2, pp. 364–366, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Venkatesha, M. Toporsian, C. Lam et al., “Soluble endoglin contributes to the pathogenesis of preeclampsia,” Nature Medicine, vol. 12, no. 6, pp. 642–649, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Gurevich and M. A. Perazella, “Renal effects of anti-angiogenesis therapy: update for the internist,” American Journal of Medicine, vol. 122, no. 4, pp. 322–328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Moake, “Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies,” Best Practice and Research: Clinical Haematology, vol. 22, no. 4, pp. 567–576, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Bollée, N. Patey, G. Cazajous et al., “Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib,” Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 682–685, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. O. Costero, M. L. Picazo, P. Zamora, S. Romero, J. Martinez-Ara, and R. Selgas, “Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy,” Nephrology Dialysis Transplantation, vol. 25, no. 3, pp. 1001–1003, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Frangié, C. Lefaucheur, J. Medioni, C. Jacquot, G. S. Hill, and D. Nochy, “Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma,” Lancet Oncology, vol. 8, no. 2, pp. 177–178, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Izzedine, I. Brocheriou, G. Deray, and O. Rixe, “Thrombotic microangiopathy and anti-VEGF agents,” Nephrology Dialysis Transplantation, vol. 22, no. 5, pp. 1481–1482, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. V. Eremina, J. A. Jefferson, J. Kowalewska et al., “VEGF inhibition and renal thrombotic microangiopathy,” New England Journal of Medicine, vol. 358, no. 11, pp. 1129–1136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. P. L. Zhang, J. W. Prichard, F. Lin et al., “Chronic active thrombotic microangiopathy in native and transplanted kidneys,” Annals of Clinical and Laboratory Science, vol. 36, no. 3, pp. 319–325, 2006. View at Google Scholar · View at Scopus
  44. B. Ducroz, P. Villemonteix, G. Magnin, and O. Pourrat, “The Hellp Syndrome: is this a clinical form of thrombotic angiopathy?” Journal de Gynecologie Obstetrique et Biologie de la Reproduction, vol. 19, no. 6, pp. 729–736, 1990. View at Google Scholar · View at Scopus
  45. Y. G. Kim, S. I. Suga, D. H. Kang et al., “Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy,” Kidney International, vol. 58, no. 6, pp. 2390–2399, 2000. View at Publisher · View at Google Scholar · View at Scopus